Novel study published in New England Journal of Medicine evaluates effects of Atacand in patients with pre-hypertension.

(From Chemical Business NewsBase - Press Release)

Results of "TROPHY" (Trial Of Preventing Hypertension) - the first study to evaluate the effects of pharmacological intervention in patients with prehypertension - were published in the New England Journal of Medicine. For the primary study end point of development of hypertension in this four-year trial, there was a significant (15.6%) relative risk reduction in the group treated with Atacand (candesartan cilexetil), compared with the group treated with placebo (53.2% vs 63%). Extensive clinical experience supporting the efficacy, safety, and tolerability of Atacand in hypertension made it an appropriate choice as …